Haemodynamic effects of pindolol in hypertensive patients. 1977

J H Atterhög, and H Dunér, and B Pernow

Five men and five women, mean age 48 years, with hypertension in stages I or II of the WHO classification, were given preoral treatment with pindolol. The pindolol treatment lead a significant decrease in the systolic and diastolic blood pressure, at rest and during work both after 2 months and after 16 months treatment. Three mechanisms seem to be involved in the antihypertensive effect of pindolol: 1) a negative chronotropic effect on the heart, 2) a decrease in peripheral vascular resistance and 3) an increase in venous capacitance affecting the venous return. Comparison of the results after 2 and after 16 months of treatment suggests that a decrease in cardiac output is an early mechanism in the lowering of the blood pressure, while a decrease in vascular resistance seems to be more important after long-term treatment with pindolol.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010869 Pindolol A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638) Prindolol,LB-46,Visken,LB 46,LB46
D002302 Cardiac Output The volume of BLOOD passing through the HEART per unit of time. It is usually expressed as liters (volume) per minute so as not to be confused with STROKE VOLUME (volume per beat). Cardiac Outputs,Output, Cardiac,Outputs, Cardiac
D005260 Female Females
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D014655 Vascular Resistance The force that opposes the flow of BLOOD through a vascular bed. It is equal to the difference in BLOOD PRESSURE across the vascular bed divided by the CARDIAC OUTPUT. Peripheral Resistance,Total Peripheral Resistance,Pulmonary Vascular Resistance,Systemic Vascular Resistance,Peripheral Resistance, Total,Resistance, Peripheral,Resistance, Pulmonary Vascular,Resistance, Systemic Vascular,Resistance, Total Peripheral,Resistance, Vascular,Vascular Resistance, Pulmonary,Vascular Resistance, Systemic

Related Publications

J H Atterhög, and H Dunér, and B Pernow
January 1982, British journal of clinical pharmacology,
J H Atterhög, and H Dunér, and B Pernow
January 1982, British journal of clinical pharmacology,
J H Atterhög, and H Dunér, and B Pernow
August 1980, European journal of clinical pharmacology,
J H Atterhög, and H Dunér, and B Pernow
November 1970, Postgraduate medical journal,
J H Atterhög, and H Dunér, and B Pernow
August 1981, Angiology,
J H Atterhög, and H Dunér, and B Pernow
February 1977, British journal of clinical pharmacology,
J H Atterhög, and H Dunér, and B Pernow
October 1989, Cardiovascular drugs and therapy,
J H Atterhög, and H Dunér, and B Pernow
January 1986, Acta medica Scandinavica,
J H Atterhög, and H Dunér, and B Pernow
January 1983, Journal de pharmacologie,
J H Atterhög, and H Dunér, and B Pernow
January 1993, International journal of clinical pharmacology research,
Copied contents to your clipboard!